According to the Zhitong Finance APP, domestic brain-computer interface progress is ongoing. On May 17, the clinical and translational ward for brain-computer interfaces was established at Beijing Tiantan Hospital. This ward was jointly built by Tiantan Hospital and several domestic research institutions, making it the first ward in China to apply brain-computer interface technology in clinical settings. In the future, this ward will conduct research and clinical trials to provide innovative treatments for patients with neurological diseases such as hemiplegia.
Brain-Computer Interface (BCI) is a system that establishes a direct information transmission pathway between the brain and external devices (such as computers, robotic arms, etc.) through technological means. In simple terms, it acts as a &#34;translator&#34; between the brain and machines.
In recent years, brain-computer interface technology has developed rapidly. On May 8, scientists from Shanghai Ladder Medical Technology Co., Ltd. (referred to as &#34;Ladder Medical&#34;) showcased a video at a media communication conference, demonstrating that after more than a month of training, their brain-computer interface subject could control the &#34;Mario Kart&#34; game using their thoughts. Staff from Ladder Medical stated that this is the first prospective clinical trial of an invasive brain-computer interface in China before registration, making the company the second invasive brain-computer interface company in the world to enter the clinical stage after Elon Musk's Neuralink.
Additionally, recent media reports indicate that Apple is deeply researching brain-computer interface technology and collaborating with the startup Synchron to explore the possibility of controlling devices such as iPhones, iPads, and Vision Pro through brain signals. This cutting-edge technology is expected to provide new interaction methods for paralyzed patients and those with limited mobility.
At the policy level, Sichuan Province plans to achieve 3,000 invasive brain-computer interface surgeries per year by 2030, serving over 100,000 patients with neurodegenerative diseases and other conditions annually, with rehabilitation equipment applications exceeding 20,000 cases per year, and promoting multi-scenario applications. Since the beginning of this year, various favorable policies have been introduced, such as Beijing strengthening diversified funding support, Shanghai focusing on cutting-edge technology to establish a decision-making consultation system, and the National Medical Products Administration also releasing measures to optimize regulation and support the innovative development of high-end medical devices. Furthermore, at the end of March, the Hubei Provincial Medical Insurance Bureau released the country's first medical service pricing for brain-computer interfaces, providing policy support for the clinical application of brain-computer interface technology.
The brain-computer interface industry has broad prospects. According to forecasts from the Qianzhan Industry Research Institute, the global market size will reach USD 1.98 billion in 2023 and is expected to exceed USD 6 billion by 2028, with a five-year compound annual growth rate of 25.22%. Medical health is currently the most mature track for brain-computer interfaces. At present, the market size of brain-computer interface devices in China is at the billion-yuan level, accounting for less than one-tenth of the global market share. Institutions predict that by 2040, the comprehensive market size of brain-computer interfaces in China is expected to exceed 120 billion yuan, with an average annual compound growth rate of about 26%.
Listed companies are also actively laying out in the brain-computer interface field, primarily focusing on downstream solutions. Weisi Medical has a rich product and technology reserve in the non-invasive brain-computer interface field, having obtained dozens of related patents; Xiangyu Medical has independently developed a series of brain-computer interfaces that include several wireless EEG acquisition systems, and related products combined with exoskeleton robots are under development
Founder Securities believes that brain-machine interfaces are expected to become the core technology for the next generation of human-machine interaction, fundamentally changing the way humans interact with machines. In the short term, the application of brain-machine interface technology will mainly focus on the medical rehabilitation field; in the medium term, output-based brain-machine interface technology will expand into education, entertainment, military, and industrial sectors; in the long term, brain-machine interfaces will shift towards functional improvement and enhancement, achieving brain-machine integrated intelligence. Dongbei Securities research report points out that China's brain-machine interface industry chain has begun to take shape, and the commercialization process is accelerating.
CITIC Construction Investment states that technological advancements in the upstream of the brain-machine interface industry chain are leading to continuous breakthroughs in downstream applications. In recent years, there have been milestone achievements in domestic and international research in medical fields such as motion recovery, language communication, and hearing reconstruction. Both national and local governments have introduced multiple policies to benefit the industry’s accelerated development. Under the catalysis of technological innovation and policy dividends, domestic brain-machine interface companies are expected to gradually achieve commercial applications.
Related Hong Kong stocks in the brain-machine interface concept:
Nanjing Panda Electronics Co., Ltd. (00553): The &#34;Key Technology R&amp;D for Multi-modal Human-Machine Interaction System Integration Based on Brain-Machine Interface Technology,&#34; organized by the Planning Department of Nanjing Panda, was successfully selected for the 2022 Jiangsu Province Key R&amp;D Program for Industry Prospects and Key Core Technology Projects.
MicroPort NeuroTech (02172): The company is a leading enterprise in the field of neuro-intervention, with significant product and technological advantages, and is expected to fully enjoy the rapid development of the industry and the benefits of import substitution. It has already achieved profitability, and its performance is expected to maintain a rapid growth trend. It announced that its wholly-owned subsidiary, MicroPort NeuroTech (Shanghai), signed a partnership agreement with multiple investors on December 16, 2024, to establish an investment fund named &#34;Shenzhen Zhongjin Brain Science and Brain-like Intelligence Industry Private Equity Investment Fund Partnership (Limited Partnership).&#34; The total capital commitment of the fund is 1 billion yuan, of which MicroPort NeuroTech (Shanghai) will contribute 200 million yuan, accounting for 20% of the fund's equity.
Heartway Medical-B (06609): On June 25, 2023, China's first domestically developed interventional brain-machine interface successfully completed animal trials in Beijing. This interventional brain-machine interface was jointly developed by Professor Duan Feng's research team from the School of Artificial Intelligence at Nankai University and Heartway Medical

AAPL

China's first clinical and translational ward for brain-computer interfaces was established on May 17 at Beijing Tiantan Hospital, marking an acceleration in the commercialization process of the brain-computer interface industry chain. This ward will provide innovative treatments for patients with neurological diseases such as hemiplegia. Brain-computer interface technology has developed rapidly in recent years, with Shanghai Ladder Medical Technology Co., Ltd. demonstrating the ability of subjects to control games through thought. In addition, Apple is also researching brain-computer interface technology and plans to collaborate with the startup Synchron. On the policy level, various regions have introduced favorable policies to promote the application and development of brain-computer interface technology

- The establishment of China's first clinical brain-computer interface (BCI) ward at Beijing Tiantan Hospital marks a significant advancement in the application of BCI technology for treating neurological disorders.  
- Recent developments include a successful demonstration of a subject controlling a video game using an invasive BCI, and Apple's collaboration with Synchron to explore BCI applications for its devices.  
- The BCI market is projected to grow significantly, with estimates suggesting a rise from $1.98 billion in 2023 to over $6 billion by 2028, driven by advancements in medical applications and supportive government policies.

Zhitong

Apple

Xiangyu Medical

Interface

Northeast Securities

Founder Securities

HEARTCARE-B

Tesla

VISHEE

NANJING PANDA

Hong Kong Stock Concept Tracking | China's first clinical and translational ward for brain-computer interfaces established, industry development accelerates, commercial landing prospects are promising (with concept stocks)